Join Dr. Lizza Hendriks from Maastricht University Medical Center as she presents an in-depth overview of the evolving landscape of targeted therapies in oncology. This video covers evidence-based strategies for developing targeted drugs, the role of biomarker-agnostic therapies in non-small cell lung cancer, and the integration of data analysis in clinical practice for optimal patient outcomes.

Key Topics:
• Development of targeted drugs
• Biomarker-agnostic therapies
• Clinical data integration for better decision-making

Access a downloadable transcript of this webinar at https://targeted-therapies-lung-cancer.ime.springerhealthcare.com/#chapter2
This is episode #2 of 4, and is part is part of an ACCME- and EACCME-accredited, Independent Medical Education program entitled, Biomarker-Positive Disease: A Personalized Approach to Selecting Targeted Therapies in Lung Cancer and Beyond.

To learn more about the full program or to CLAIM YOUR CREDITS, visit https://targeted-therapies-lung-cancer.ime.springerhealthcare.com/
---
This activity is supported by independent educational grants from Roche and Illumina.